STXS - Stereotaxis, Inc.
Dopo ore:
| Chiusura precedente | 2,2700 |
| Aperto | 2,2600 |
| Denaro | 2,0400 x 1800 |
| Lettera | 2,4100 x 2900 |
| Min-Max giorno | 2,1500 - 2,2600 |
| Intervallo di 52 settimane | 1,5500 - 2,7500 |
| Volume | |
| Media Volume | 281.073 |
| Capitalizzazione | 179,106M |
| Beta (5 anni mensile) | 1,63 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,2600 |
| Prossima data utili | 07 ago 2023 - 11 ago 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 5,25 |
GlobeNewswireStereotaxis to Participate in 20th Annual Craig-Hallum Institutional Investor Conference
ST. LOUIS, May 25, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in Craig-Hallum’s 20th Annual Institutional Investor Conference. Mr. Fischel will be available on Wednesday, May 31, 2023 for one-on-one meetings with conference attendees. “We appreciate the invitation by Craig-Hallum and look forward to sharing Stereotaxis’
- GlobeNewswire
Advocate Christ Medical Center Extends Leadership in Heart Care with Adoption of Genesis Robotic Technology
ST. LOUIS, May 23, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment of cardiac arrhythmias, today announced the first treatment of patients with a newly launched Genesis Robotic Magnetic Navigation (RMN) system at Advocate Christ Medical Center in Chicago, Illinois. Advocate Christ Medical Center, a part of Advocate Health, is the leading provider of robotic heart rhythm care in the Midwest. Electrophysiologists at the hospital have t
- GlobeNewswire
Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms
ST. LOUIS, May 19, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT) to integrate Abbott’s EnSite™ X EP System with Stereotaxis’ Robotic Magnetic Navigation systems. The combination of Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery. Technology integr
- GlobeNewswire
Stereotaxis Reports 2023 First Quarter Financial Results
ST. LOUIS, May 09, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2023. “Stereotaxis continues to make significant progress on its robust innovation strategy. We have responded to all outstanding regulatory questions for CE Mark review of the MAGiC catheter and completed the preclinical studies required for an IDE submission
- GlobeNewswire
Stereotaxis to Report First Quarter 2023 Financial Results on May 9, 2023
ST. LOUIS, April 18, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 first quarter on Tuesday, May 9, 2023 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company’s results and corporate developments. What: Stereotaxis first quarter 2023 fi
- GlobeNewswire
Over 1,000 Cardiac Patients Treated with Genesis Robotic System
ST. LOUIS, April 13, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that over 1,000 cardiac arrhythmia patients have been treated using the Genesis Robotic Magnetic Navigation (RMN) system. Genesis RMN, the latest innovation in Stereotaxis’ robotic technology, was first used in late 2020 following regulatory clearances in the United States and Europe. Since then, physicians at e
- GlobeNewswire
Broward Health Medical Center the First Hospital in Florida Using Advanced Genesis Robotic Technology to Treat Heart Rhythm Disorders
ST. LOUIS, March 20, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the grand opening of a new robotic electrophysiology program at Broward Health Medical Center in Fort Lauderdale, Florida. Broward Health is among the first in the nation, and the first in Florida, to offer the latest Genesis Robotic Magnetic Navigation System to treat heart rhythm disorders. “Advancing patient care
- GlobeNewswire
Stereotaxis Reports 2022 Full Year Financial Results
ST. LOUIS, March 03, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2022. “This year is poised to be an important and exciting year for Stereotaxis, as we bring multiple strategic innovations to key regulatory and commercial milestones,” said David Fischel, Chairman and CEO. “This transition to a new produc
- GlobeNewswire
Stereotaxis to Present at Cowen 43rd Annual Health Care Conference
ST. LOUIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Cowen 43rd Annual Health Care Conference. Mr. Fischel will present on Stereotaxis’ business and technology during a Fireside Discussion with Josh Jennings, Cowen’s Managing Director & Senior Research Analyst, on Monday, March 6, 2023, at 11:10 am ET. M
- GlobeNewswire
Stereotaxis to Report Fourth Quarter and Full Year 2022 Financial Results on March 3, 2023
ST. LOUIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 fourth quarter and full year ended December 31, 2022 on Friday, March 3, 2023 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company’s results and corporate developments.
- GlobeNewswire
Corewell Health Grows Robotic Program to Treat Heart Rhythm Disorders with Adoption of Stereotaxis’ Genesis System
ST. LOUIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of patients using the latest Genesis Robotic Magnetic Navigation (RMN) system by physicians of the nationally recognized Fred & Lena Meijer Heart Center, part of Corewell Health in Grand Rapids, Michigan. Electrophysiologists at Corewell Health have established a successful robotic cardiac ablation prog
- GlobeNewswire
Stereotaxis to Participate in Piper Sandler 34th Annual Healthcare Conference
ST. LOUIS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 34th Annual Healthcare Conference. Mr. Fischel will present on Stereotaxis’ business and technology during a Fireside Discussion on Thursday, December 1, 2022, at 9:00 am ET. He will then join a panel discussion on “The Future of Robotic
- GlobeNewswire
Stereotaxis Reports 2022 Third Quarter Financial Results
ST. LOUIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2022. “Stereotaxis continues to demonstrate robust commercial and technological progress,” said David Fischel, Chairman and CEO. “We received two system orders in the third quarter, and have already received two additional signed purchase contracts as we
- GlobeNewswire
Stereotaxis to Report Third Quarter Financial Results on November 10, 2022
ST. LOUIS, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 third quarter on Thursday, November 10, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company’s results and corporate developments. What:Stereotaxis third quarter 20
- GlobeNewswire
Stereotaxis Receives St. Louis Mayor’s Innovation Award for 2022
ST. LOUIS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it was awarded the 2022 Innovation Award from the Office of the Mayor of St. Louis, Tishaura O. Jones. This recognition reflects Stereotaxis’ regional leadership in advancing cutting-edge technologies with a positive impact on society. Stereotaxis’ Robotic Magnetic Navigation technology is most known for introduc
- GlobeNewswire
International Meeting of the Society for Cardiac Robotic Navigation to Showcase Stereotaxis Technology and Its Clinical Value
ST. LOUIS, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its attendance at the Sixth Annual International Meeting of the Society for Cardiac Robotic Navigation (SCRN) in Budapest from September 29-30. SCRN is an independent, non-profit, physician-led organization with global membership and local chapters in North America, Europe and Asia. SCRN was formed with the miss
- GlobeNewswire
Overland Park Regional Medical Center Extends Leadership in Robotic Treatment of Heart Rhythm Disorders with Plans for Second Stereotaxis System
ST. LOUIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Overland Park Regional Medical Center (OPRMC) is establishing its second robotic program for the treatment of heart rhythm disorders. OPRMC, a part of HCA Midwest Health, first established a robotic heart rhythm care program in 2019. Since then, it has built a leading practice that applies advanced robotic
GlobeNewswireStereotaxis Reports 2022 Second Quarter Financial Results
ST. LOUIS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2022. “Despite macro pressures and the poor optics of our financial results, Stereotaxis is making significant progress commercially and technologically,” said David Fischel, Chairman and CEO. “I am pleased with our progress and confident in where we stand an
- GlobeNewswire
Industry Veterans Join Stereotaxis Commercial Leadership Team as Company Advances Robust Innovation Pipeline
ST. LOUIS, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the significant enhancement of its commercial leadership team with the successful recruitment of two veterans of the medical device, surgical robotics and electrophysiology fields. Joining Stereotaxis are experienced commercial leaders with relevant and complementary expertise: Frank Van Hyfte is joining as Vice
- GlobeNewswire
Stereotaxis to Report Second Quarter Financial Results on August 9, 2022
ST. LOUIS, July 19, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 second quarter on Tuesday, August 9, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. ET that day to discuss the Company’s results and corporate developments. What: Stereotaxis second quarter 2022
GlobeNewswireStereotaxis Announces CE Mark Submission for Robotically Navigated MAGiC Ablation Catheter
Stereotaxis Robotically Navigated MAGiC Catheter for Cardiac Ablation Stereotaxis has announced CE Mark submission for its novel, robotically navigated MAGiC ablation catheter for the treatment of cardiac arrhythmias. Design features include a round, solid gold tip with 25 irrigation ports and string-of-pearls distribution of magnetic material along the catheter’s flexible shaft. Stereotaxis Robotic Magnetic Navigation System Procedure room equipped with Stereotaxis Robotic Magnetic Navigation (
GlobeNewswireJournal of Atrial Fibrillation & Electrophysiology Publishes Special Issue Dedicated to Robotics in EP
16 Peer-Reviewed Publications Highlight Clinical Value of Robotic Magnetic Navigation for Heart Rhythm DisordersST. LOUIS, June 06, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces the publication of a special issue of the Journal of Atrial Fibrillation & Electrophysiology (JAFIB-EP) focused on the use of Robotic Magnetic Navigation (RMN) for the treatment of cardiac arrhythmias. The Roboti